Education
About Us
Working with TipRanks
Follow Us
BeOne Medicines (ONC)
:ONC
ONC Stock Chart & Stats
$335.17
--
Market closed
$335.17
--
Day’s Range― - ―
52-Week Range$170.99 - $385.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)282.05K
Market Cap
$39.17B
Enterprise Value$36.83B
Total Cash (Recent Filing)$4.04B
Total Debt (Recent Filing)$1.02B
Price to Earnings (P/E)644.8
Beta0.83
Next Earnings
Apr 01, 2026EPS Estimate
1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.09
Shares Outstanding109,663,280
10 Day Avg. Volume392,731
30 Day Avg. Volume282,051
Financial Highlights & Ratios
PEG Ratio1.09
Price to Book (P/B)5.84
Price to Sales (P/S)5.10
P/FCF Ratio-29.04
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue7.41
Enterprise Value/Gross Profit8.59
Enterprise Value/Ebitda122.23
Forecast
1Y Price Target
$394.97Price Target Upside17.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company's redomiciliation to Switzerland has been well received by all stakeholders, with globalization accelerating and significant revenue contributions from the US and EU.
Pipeline InnovationManagement is committed to bringing 8-10 new molecules into the clinic each year, sustaining a pipeline designed for innovation.
Product PerformanceBrukinsa surpassed $1B revenue, becoming the No.1 revenue-generating BTKi in the global market.
Bears Say
BeOne Medicines News
ONC FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $170.99 and its highest was $385.22 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $39.17B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Apr 01, 2026 which is in 125 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on Nov 06, 2025. The company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.851 by $0.239.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 1.41.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,663,280 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $1.09 in its last earnings report, beating expectations of $0.851. Following the earnings report the stock price went up 3.413%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in ONC
BeOne Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$394.97 (17.84% Upside)
$394.97 (17.84% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 479.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 23.3%
Last 30 Days ▲ 23.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.64%
12-Months-Change
Fundamentals
Return on Equity
1.84%
Trailing 12-Months
Asset Growth
30.90%
Trailing 12-Months
Company Description
BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
ONC Company Deck
ONC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights strong financial performance with record revenue growth and a solid cash position. Significant achievements in R&D and FDA breakthrough designation for Sonro are positive. However, there are challenges in competitive markets and delays in some studies. Overall, the highlights outweigh the lowlights, indicating a positive outlook.View all ONC earnings summariesONC Stock 12 Month Forecast
Average Price Target
$394.97
▲(17.84% Upside)